Is Inferior Mesenteric Artery Embolization Indicated Prior to Endovascular Repair of Abdominal Aortic Aneurysm?

Biancari, F.

2015-11


http://hdl.handle.net/10138/159272
https://doi.org/10.1016/j.ejvs.2015.06.116

Downloaded from Helda, University of Helsinki institutional repository.
This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail.
Please cite the original version.
Type II endoleak is a common condition occurring after endovascular repair of abdominal aortic aneurysms (EVAR), and may result in aneurysm sac growth and/or rupture in a small number of patients. A prophylactic strategy of inferior mesenteric artery (IMA) embolization before EVAR has been advocated, however, the benefits of this strategy are controversial. A clinical vignette allows the authors to summarize the available data about this issue and discuss the possible benefits and risks of prophylactic IMA embolization before EVAR. The authors performed a meta-analysis of available data which showed that the pooled rate of type II endoleak after IMA embolization was 19.9% (95% CI 3.4–34.7%, \( I^2 \) 93%) whereas it was 41.4% (95% CI 30.4–52.3%, \( I^2 \) 76%) in patients without IMA embolization (5 studies including 596 patients: \( p < .0001, OR \) 0.369, 95% CI 0.22–0.61, \( I^2 \) 27%). Since treatment for type II endoleaks is needed in less than 20% of cases and this complication can be treated successfully in 60–70% of cases resulting in an aneurysm rupture risk of 0.9%, these data indicate that embolization of patent IMA may be of no benefit in patients undergoing EVAR.

**PROGNOSTIC IMPACT OF TYPE II ENDOLEAK**

Studies regarding the significance of type II endoleak have shown contradictory results. Some studies have shown that type II endoleaks are associated with a benign course. However, most studies are in agreement that type II
endoleak may result in persistently elevated intra-sac pressure and failure of aneurysm sac shrinkage. A few studies concluded that persistent type II endoleak is associated with adverse outcomes such as aneurysm sac growth and rupture and therefore requires re-intervention.

In a recent meta-analysis of 32 studies including 21,744 patients, type II endoleak after EVAR was detected in 10.2% of patients. About 35% of these endoleaks resolved spontaneously. Three hundred and ninety-three (26%) interventions for type II endoleak were performed with a success rate of 71.5%. Fourteen patients (0.9%) with isolated type II endoleak had ruptured abdominal aortic aneurysm, six of them without any sign of aneurysm sac growth. Another meta-analysis was not able to define a threshold for treatment of type II endoleak as the aggressive treatment of type II endoleak not associated with sac expansion did not provide better results than a more conservative strategy (intervention only in cases of type II endoleak with sac expansion > 5 mm or persistent type II endoleak for > 12 months). No aneurysm rupture occurred in this pooled series. However, type II endoleak associated with an aneurysm sac growth ≥ 10 mm is considered an indication for endovascular, laparoscopic or open repair.

**IMPACT OF INFERIOR MESENTERIC EMBOLIZATION PRIOR TO EVAR IN PREVENTING TYPE II ENDOLEAK**

Although EVAR has been performed for almost three decades, there are only five studies adequately comparing the outcome of IMA embolization with a conservative strategy. The results of these series have been pooled here using the random effects method. Statistical analysis was performed using Open meta-analysis statistical software (http://www.cebm.brown.edu/open_meta). These five studies reported on 246 patients who underwent IMA embolization with or without embolization of patent lumbar arteries and their outcome was compared with that of 350 patients with patent IMA and who did not undergo prophylactic embolization of the aortic branches. Two studies performed IMA embolization with Amplazer and the others by coiling. In a few cases, embolization of lumbar arteries was performed as well. The embolization procedure had a success rate of 98.4% (95% CI 96.3–100%). The rate of type II endoleak after IMA embolization was 19.9% (95% CI 3.4–34.7%, \( i^2 \) 93%) whereas it was 41.4% (95% CI 30.4–52.3%, \( i^2 \) 76%) in patients without IMA embolization (\( p < .0001, \) OR 0.369, 95% CI 0.222–0.613, \( i^2 \) 27%) (Fig. 1). Lumbar arteries were responsible for type II endoleak in a few patients. Four studies reported on the number of patients who required re-intervention for type II endoleak and this was significantly lower after IMA embolization (1.2% vs. 13.4%, \( p < .0001, \) OR 0.091, 95% CI 0.027–0.301, \( i^2 \) 0%). However, the threshold for intervention varied significantly between studies. Two studies reported on aneurysm related mortality, which was nil in both. One patient developed mesenteric ischemia after IMA embolization and died. No homogeneous data were reported on the rate of growth of the aneurysm sac in these studies. In one study, the overall linearized aneurysm shrinkage rate was 1.4 ± 3.8 mm per year in the IMA embolization group and 1.7 ± 2.4 mm per year in the control group (\( p < .72 \)).

**DIAMETER OF THE INFERIOR MESENTERIC ARTERY AND OCCURRENCE OF TYPE II ENDOLEAK**

The impact of the size of IMA on the occurrence of type II endoleak is a matter of intense debate. Fukuda et al. observed that the diameter of the proximal IMA was larger than 2.5 mm in 24% (26/106) of patients without type II endoleak, in 50% of those with transient endoleak (5/10), and 100% (5/5) in patients with persistent endoleak. In multivariate analysis, the absence of stenosis of the IMA at its orifice was more likely to be a significant factor of persistent type II endoleak (\( p = .0003 \)) and thrombus at the orifice of the IMA was a negative predictor of persistent type II endoleak (\( p = .043 \)). Otsu and colleagues confirmed these findings and showed that an IMA diameter > 2.5 mm along with each additional patent lumbar artery ≥ 1.9 mm were predictors of permanent type II endoleak. Similarly, Müller-Wille and colleagues observed that patients without complex IMA and lumbar artery type II endoleak in whom the largest feeding and/or draining artery was larger than 3.8 mm, and patients with a complex IMA type II endoleak in whom the largest feeding and/or draining artery was larger than 2.2 mm were at high risk for aneurysm sac enlargement.

Another study showed the significant association between the diameter of the IMA and the occurrence of type II endoleak. However, multivariate analysis showed that the number and diameter of patent lumbar arteries were the only predictors of permanent type II endoleak requiring...
Inferior Mesenteric Artery Embolization

A few serious complications have been reported after embolization of the IMA. Post-operative death secondary to colonic ischemia has been reported as a result of catheter directed embolization of the IMA prior to EVAR, and for treatment of type II endoleak. Overall, the incidence of mesenteric ischemia in extremely low. Aortitis has been observed after percutaneous endovascular coil embolization prior to EVAR. Since IMA embolization is associated with a significantly increased use of contrast agent, the potential risk of acute kidney injury should be considered in the decision making process in patients with decreased renal function.

Cost related issues with inferior mesenteric artery embolization

The cost of pre-operative embolization with an Amplatzer device has been estimated to be about 300 euros and of coils ranging from 360 to 600 euros. However, considering the current clinical practice in which type II endoleaks are actively treated only in case of aneurysm growth, it is evident that routine pre-operative IMA embolization is not cost-effective.

Clinical decision in this patient

The present patient is rather young, but has a history of myocardial infarction and of moderate renal failure, which may increase his operative and late mortality risk. He has been a heavy smoker and this may further decrease his life expectancy. If it is assumed that his moderate renal insufficiency is equivalent to a creatinine serum level > 150 µmol/L, the Glasgow Aneurysm Score would be 88. According to the Eurostar registry data, the 30 day mortality risk of this patient would be about 5% and his 6 year survival would be about 60%. Such a high operative risk suggests that he most certainly would benefit from a straightforward EVAR without IMA embolization. This strategy would also prevent any further risk of acute kidney injury possibly associated with the use of a larger amount of contrast.

There are a few data showing that smoking habit is associated with a lower risk of type II endoleak after EVAR. Such a lower risk of endoleak can be related to the decreased perfusion of the IMA and lumbar arteries in previous and current smokers compared with non-smokers. Indeed, universal atherosclerosis in heavy smokers may affect the visceral arteries and impair the retrograde collateral circulation to the aneurysm sac. Since this patient has been a heavy smoker, it may be expected that his risk of developing a type II endoleak secondary to a patent IMA is significantly reduced.

Pooled analysis of available data indicates that IMA embolization is associated with significantly lower risk of type II endoleak, but the pooled rate of this event is still about 20% among these patients and other aortic branches may be responsible for endoleak. Therefore, type II endoleak cannot be prevented in all patients solely by IMA embolization. Indeed, large lumbar arteries are associated with the occurrence of type II endoleak, and their contribution may be more significant than the IMA. Therefore, accurate imaging evaluation of the lumbar arteries is needed to better estimate the real value of IMA embolization when a large number of lumbar arteries are patent.

Since treatment for type II endoleaks is needed in less than 20% of cases and this complication can be treated successfully in 60—70% of cases, resulting in an aneurysm rupture risk of 0.9%, it is believed that embolization of patent IMA before EVAR is not indicated in this high risk patient.

Conflict of interest

None.

Funding

None.

References


